Department of Sense Organs, University Sapienza of Rome , Rome , Italy.
Expert Rev Neurother. 2019 Nov;19(11):1127-1133. doi: 10.1080/14737175.2019.1648210. Epub 2019 Aug 12.
: Neuromyelitis optica spectrum disorders (NMOSD) are autoimmune diseases of the central nervous system mainly involving the optic nerves and spinal cord. Many advances have been made in understanding the immunopathology of NMOSD and related clinical classification, nevertheless, open issues in management and effective therapeutic approaches still remain. : In this article, the authors reviewed and discussed the scientific evidence in pathogenesis and pharmacological therapy of NMOSD addressing the more recent advances in new biological treatment option and therapeutic strategy that may help to improve management of this condition. : Despite current immunopathogenic evidence, NMOSD management represents a challenge due to the poor-validated diagnostic, prognostic and therapeutic biomarkers. A tailored approach is mandatory to improve the management of the different disease clinical settings.
视神经脊髓炎谱系疾病（NMOSD）是一种主要累及视神经和脊髓的中枢神经系统自身免疫性疾病。尽管在 NMOSD 的免疫病理学和相关临床分类方面已经取得了许多进展，但在管理和有效治疗方法方面仍存在一些悬而未决的问题。本文作者回顾和讨论了 NMOSD 发病机制和药物治疗的科学证据，重点介绍了新型生物治疗选择和治疗策略方面的最新进展，这些进展可能有助于改善该疾病的管理。尽管目前有免疫发病机制方面的证据，但 NMOSD 的管理仍然是一个挑战，因为缺乏经过充分验证的诊断、预后和治疗生物标志物。因此，必须采取个体化的方法来改善不同疾病临床环境的管理。
